Rituximab Induced Interstitial Lung Disease in Patients with Non-Hodgkin’s Lymphoma: A Clinical Study of Six Cases and Review of the Literature

Table 3

Clinical and radiological profile of patients with rituximab-induced interstitial lung disease.

Age and gender	Histology	Stage	Protocol	Cycle at onset	Onset after 1st rituximab infusion (days)	Onset after preceding rituximab infusion (days)	Clinical features	Thoracic high resolution computed tomography findings	Outcome	Rituximab rechallenge
69, M	MZL	IV	R-CHOP	6	150	16	Dyspnea	Bilateral ground glass opacities	Remission	Yes, no recurrence
76, F	DLBCL	IV	R-CHOP	2	30	15	Dyspnea, fever, and rhonchi	Bilateral ground glass opacities bilateral minimal pleural effusion	Remission	No
62, M	FL	IIIB	R-CHOP	3	43	17	Dyspnea, dry cough, fatigue, and crackles	Bilateral ground glass opacities emphysema	Remission	Yes, no recurrence
71, M	DLBCL	IV	R-CHOP	4	72	17	Fever and fatigue	Bilateral ground glass opacities	Remission	No
42, M	DLBCL	IIIA	R-CHOP	3	54	22	Fever	Bilateral ground glass opacities	Remission	No
61, M	DLBCL	IIIA	R-CHOP	3	58	27	Fever, productive cough, and crackles	Bilateral ground glass opacities	Death	No

M: male, F: female, MZL: marginal zone lymphoma, DLBCL: diffuse large B cell lymphoma, FL: follicular lymphoma, R-CHOP: rituximab (375 mg/sq.m), cyclophosphamide (750 mg/sq.m), hydroxy daunorubicin (50 mg/sq.m), oncovin (1.4 mg/sq.m), and prednisolone (100 mg on days 1 to 5).